{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:14Z","timestamp":1790310074117,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":680,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003We report the first-in-human safety and immunogenicity evaluation of a highly attenuated, replication-competent recombinant vesicular stomatitis virus (rVSV) human immunodeficiency virus (HIV)-1 vaccine.<\/jats:p>\n               <jats:p>Methods. \u2003Sixty healthy, HIV-1-uninfected adults were enrolled in a randomized, double-blinded, placebo-controlled dose-escalation study. Groups of 12 participants received rVSV HIV-1 gag vaccine at 5 dose levels (4.6 \u00d7 103 to 3.4 \u00d7 107 particle forming units) (N = 10\/group) or placebo (N = 2\/group), delivered intramuscularly as bilateral injections at 0 and 2 months. Safety monitoring included VSV cultures from blood, urine, saliva, and swabs of oral lesions. Vesicular stomatitis virus-neutralizing antibodies, T-cell immunogenicity, and HIV-1 specific binding antibodies were assessed.<\/jats:p>\n               <jats:p>Results. \u2003Local and systemic reactogenicity symptoms were mild to moderate and increased with dose. No severe reactogenicity or product-related serious adverse events were reported, and all rVSV cultures were negative. All vaccine recipients became seropositive for VSV after 2 vaccinations. gag-specific T-cell responses were detected in 63% of participants by interferon-\u03b3 enzyme-linked immunospot at the highest dose post boost.<\/jats:p>\n               <jats:p>Conclusions. \u2003An attenuated replication-competent rVSV gag vaccine has an acceptable safety profile in healthy adults. This rVSV vector is a promising new vaccine platform for the development of vaccines to combat HIV-1 and other serious human diseases.<\/jats:p>","DOI":"10.1093\/ofid\/ofv082","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T20:36:26Z","timestamp":1485981386000},"source":"Crossref","is-referenced-by-count":62,"title":["First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)"],"prefix":"10.1093","volume":"2","author":[{"given":"Jonathan D.","family":"Fuchs","sequence":"first","affiliation":[{"name":"San Francisco Department of Public Health, California"},{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Frank","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnie L.","family":"Elizaga","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Frahm","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Kochar","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Li","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilatha","family":"Edupuganti","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros A.","family":"Kalams","sequence":"additional","affiliation":[{"name":"Vanderbilt University, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sheets","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pensiero","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Profectus Biosciences, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Higgins","sequence":"additional","affiliation":[{"name":"Profectus Biosciences, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Latham","sequence":"additional","affiliation":[{"name":"Profectus Biosciences, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Egan","sequence":"additional","affiliation":[{"name":"Profectus Biosciences, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Profectus Biosciences, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Eldridge","sequence":"additional","affiliation":[{"name":"Profectus Biosciences, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scharla","family":"Estep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Rybczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deb","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese","family":"Isbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Chinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramey","family":"Fair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Briesemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,6,5]]},"reference":[{"key":"2020081006372491600_OFV082C1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/5557","article-title":"Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques","volume":"5","author":"Baba","year":"1999","journal-title":"Nat Med"},{"key":"2020081006372491600_OFV082C2","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1128\/JVI.02345-08","article-title":"Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens","volume":"83","author":"Mooij","year":"2009","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"2020081006372491600_OFV082C4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM196711092771901","article-title":"Human infection with the virus of vesicular stomatitis during an epizootic","volume":"277","author":"Fields","year":"1967","journal-title":"N Engl J Med"},{"key":"2020081006372491600_OFV082C5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4269\/ajtmh.1987.36.177","article-title":"Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups","volume":"36","author":"Reif","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"2020081006372491600_OFV082C6","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J Infect Dis"},{"key":"2020081006372491600_OFV082C8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-006-0042-3","article-title":"Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector","volume":"28","author":"Clarke","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"2020081006372491600_OFV082C9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/aid.2004.20.989","article-title":"Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes","volume":"20","author":"Egan","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081006372491600_OFV082C10","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1128\/JVI.76.6.2730-2738.2002","article-title":"High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses","volume":"76","author":"Haglund","year":"2002","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"2020081006372491600_OFV082C12","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C14","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1128\/JVI.03441-13","article-title":"Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in non-human primates","volume":"88","author":"Clarke","year":"2014","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J Virol Methods"},{"key":"2020081006372491600_OFV082C16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/IAI.13.4.1242-1249.1976","article-title":"Comparison of central nervous system disease produced by wild-type and temperature-sensitive mutants of vesicular stomatitis virus","volume":"13","author":"Rabinowitz","year":"1976","journal-title":"Infect Immun"},{"key":"2020081006372491600_OFV082C17","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.1128\/JVI.74.23.10903-10910.2000","article-title":"Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1","volume":"74","author":"Rose","year":"2000","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cyto.a.22218","article-title":"OMIP-014: validated mu.jpegunctional characterization of antigen-specific human T cells by intracellular cytokine staining","volume":"81","author":"De Rosa","year":"2012","journal-title":"Cytometry A"},{"key":"2020081006372491600_OFV082C19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to qua.jpegy antigen-specific T cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"2020081006372491600_OFV082C20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2007.02.003","article-title":"Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials","volume":"322","author":"Bull","year":"2007","journal-title":"J Immunol Methods"},{"key":"2020081006372491600_OFV082C21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"2020081006372491600_OFV082C22","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"HIV transmission induces selective recognition of gp41 with minimal impact on acute phase viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"2020081006372491600_OFV082C23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe- preliminary report","author":"Agnandji","year":"2015","journal-title":"N Engl J Med"},{"key":"2020081006372491600_OFV082C24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nri2636","article-title":"Monkeying around with HIV vaccines: using rhesus macaques to define \u2018gatekeepers\u2019 for clinical trials","volume":"9","author":"Shedlock","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2020081006372491600_OFV082C25","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1016\/j.vaccine.2010.09.079","article-title":"Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans","volume":"28","author":"Bett","year":"2010","journal-title":"Vaccine"},{"key":"2020081006372491600_OFV082C26","doi-asserted-by":"crossref","article-title":"An HIV DNA vaccine delivered by electroporation and boosted by rVSV HIV-1 Gag is safe and immunogenic in healthy HIV-uninfected adults","author":"Hay","DOI":"10.1089\/aid.2014.5019.abstract"},{"key":"2020081006372491600_OFV082C27","doi-asserted-by":"crossref","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med"},{"key":"2020081006372491600_OFV082C28","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"2020081006372491600_OFV082C29","doi-asserted-by":"crossref","first-page":"e2600","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"19","author":"Mire","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020081006372491600_OFV082C30","doi-asserted-by":"crossref","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates","volume":"9","author":"Mire","year":"2014","journal-title":"PLoS One"},{"key":"2020081006372491600_OFV082C31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"Mire","year":"2015","journal-title":"Nature"},{"key":"2020081006372491600_OFV082C32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine \u2013 preliminary report","author":"Regules","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/3\/ofv082\/33621612\/ofv082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/3\/ofv082\/33621612\/ofv082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T10:46:46Z","timestamp":1597056406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofv082\/2460236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofv082","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015]]},"published":{"date-parts":[[2015]]},"article-number":"ofv082"}}